Tranexamic acid (TXA) is an antifibrinolytic agent that inhibits clot breakdown and is well described in the literature toreduce intraoperative blood loss in craniofacial, cardiac, trauma, dermatologic, and orthopedic surgeries.
Practice Focus » Facial Plastic/Reconstructive
In mid and upper face reconstruction, vascular grafting, targeting more distal branches of the facial system, or additional maneuvers to optimize pedicle orientation is often required to secure revascularization.
Operative middle and upper maxillofacial trauma decreased over a 17-year period, with assault identified as the most significant mechanism of trauma overall.
Significant disparities exist in medical school enrollment for minority students and achievement of full professorship in otolaryngology, surgery, and internal medicine.
The practice of discontinuing estrogen therapy for two weeks prior to surgery should be weighed against individual risk factors, mode of administration, and side effects.
Recent prospective clinical studies have not found an increased incidence of facial scarring in patients using isotretinoin in the perioperative period.